Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Two More Member States Join US-EU Inspections Deal

Executive Summary

The number of European countries whose drug manufacturing site inspections the US regulator can rely on in place of its own inspections has grown.

You may also be interested in...



More Countries Join US-EU Inspections Deal

There are now just two European countries left to join the agreement between the EU and the US on recognizing the findings of inspectorates in each other’s jurisdictions.

US FDA's New Global Office Aims To Elevate and Enhance Agency’s Role On World Stage

There is growing recognition that the US FDA can use trade agreements to help confront the challenges of globalization and that these agreements can play an increasingly important role in fostering regulatory alignment and improving the quality of imports, agency official says.

US Yes To Two More Countries Under EU Inspections Deal

The US drug regulator may now rely on a total of 22 EU member states whose inspection results can replace its own inspections.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS125208

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel